Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Metastatic Cutaneous Squamous Cell Carcinoma. J of Skin 2018, 2, S79. https://doi.org/10.25251/skin.2.supp.79.